Medical Doctor Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Sonia Silinsky Krupnikova

Internal Medicine Wheaton, MD Medical Doctor

NPI 1477085918 CMS profile 8411955

2730 University Blvd W Ste 310, Wheaton, MD 20902

Open in the dashboard

General payments

$1,283

13 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Sonia Silinsky Krupnikova of Wheaton, MD is reported in the CMS Open Payments database as having received $1,283 across 13 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 73rd percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $588 8
2024 General $142 1
2023 General $434 3
2022 General $119 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sonia Silinsky Krupnikova
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Sonia Silinsky Krupnikova were reported at $588. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Sonia Silinsky Krupnikova Internal Medicine median Middle half National median
2019 $0 $159 $48–$570 $163
2020 $0 $119 $33–$402 $114
2021 $0 $135 $37–$521 $132
2022 $119 $141 $42–$496 $149
2023 $434 $149 $45–$519 $160
2024 $142 $154 $47–$537 $164
2025 $588 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. Horizon Therapeutics plc $320 2 payments
  2. Amgen Inc. $284 3 payments
  3. Janssen Biotech, Inc. $241 2 payments
  4. Aurinia Pharma U.S., Inc. $232 2 payments
  5. UCB, Inc. $151 1 payment
  6. AbbVie, Inc. $34 2 payments
  7. Werfen USA LLC $20 1 payment

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $1,184 12 payments
  2. Education $99 1 payment
Products named General payments · program years 2022–2025
  1. TREMFYA $241 2 payments
  2. TAVNEOS $146 1 payment
  3. SIMPONI ARIA $142 1 payment
  4. KRYSTEXXA Krystexxa $125 1 payment
  5. RINVOQ $34 2 payments
  6. KRYSTEXXA Inflammation/Rare Disease $18 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 13 drugs

Part D claims

641

Median for Rheumatology: 1,511

Drug cost

$125,512

Median for Rheumatology: $1,139,948

Branded share of claims

14.7%

Median for Rheumatology: 28.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Humira(Cf) Pen Adalimumab Brand 12 $81,738
Teriparatide Generic 12 $26,435
Methotrexate Methotrexate Sodium Brand 82 $3,836
Hydroxychloroquine Sulfate Generic 47 $3,109
Colchicine Generic 29 $2,697
Celecoxib Generic 58 $2,508
Duloxetine Hcl Generic 47 $1,835
Allopurinol Generic 63 $803
Gabapentin Generic 49 $653
Prednisone Generic 87 $559

The 10 drugs with the highest cost, of 13 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 5,224 Part D prescribers listed as Rheumatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 116 billing codes

Paid by Medicare

$714,991

Of which drugs: $521,505

Medicare patients

496

Average age 76

Services billed

44,852

430 women, 66 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Osteoporosis 60%
Diabetes 27%
Depression 25%
Chronic kidney disease 22%
Ischemic heart disease 21%
Cancer 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, denosumab, 1 mg J0897 Office 83 5,760 $115,035
Injection, romosozumab-aqqg, 1 mg J3111 Office 28 9,870 $82,185
Injection, zoledronic acid, 1 mg J3489 Office 55 275 $1,359
Injection, methylprednisolone acetate, 1 mg J1010 Office 68 5,294 $545

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TREMFYA
  • Janssen Biotech, Inc. $71
$71 — —
SIMPONI ARIA
  • Janssen Biotech, Inc. $71
$71 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

13 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Maryland

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record